Poland · Delayed Price · Currency is PLN Selvita Company Description
Selvita S.A. operates as a contract research organization worldwide.
The company offers drug discovery services in the areas of AI-driven drug discovery, antibody drug discovery, structural biology, recombinant protein production, assay development and screening, computer-aided drug design, medicinal and synthetic chemistry, scale-up, ADME/DMPK, in vitro and In Vivo pharmacology, translational research, and toxicology.
It also develops drugs for therapeutic areas, such as oncology, infectious diseases, immunology, neurology, respiratory, and other.
In addition, the company provides drug development services, including formulation development; CMC analytical support; stability and shelf-life determination; clinical supply/GMP manufacturing; small molecules bioanalysis; drug substance and product; and biologics and biosimilars bioanalysis services.
Further, it offers research and development services in the areas of agrochemistry analytical support, and flavor and fragrance chemistry.
The company was formerly known as Selvita CRO S.A. and changed its name to Selvita S.A. in October 2019.
Selvita S.A. was founded in 2007 and is based in Kraków, Poland.
| Country | Poland |
| Founded | 2007 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 969 |
| CEO | Boguslaw Sieczkowski |
Contact Details
Address: Hexagon Kraków, 30-394 Poland | |
| Phone | 48 123 00 50 01 |
| Website | selvita.com |
Stock Details
| Ticker Symbol | SLV |
| Exchange | Warsaw Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | PLN |
| ISIN Number | PLSLVCR00029 |
| SIC Code | 8731 |
Key Executives
| Name | Position |
|---|---|
| Boguslaw Stanislaw Sieczkowski M.B.A. | Chairman of Management Board and Chief Executive Officer |
| Dr. Milosz Kazimierz Gruca Ph.D. | Global Head of Drug Development, Executive Vice President and Vice President of Management Board |
| Dariusz Tomasz Kurdas | Chief Financial Officer and Member of the Management Board |
| Dawid Patryk Radziszewski | General Counsel and Member of the Management Board |
| Dr. Adrijana Vinter | Global Head of Drug Discovery and Member of the Management Board |
| Natalia Walas - Marcinek | Executive Officer |
| Marija Gradecak Galovic | Executive Officer |
| Anna Leja | Executive Officer |
| Tomasz Narojczyk | Executive Officer |
| Dr. Paul D. Overton Ph.D. | Chief Commercial Officer |